Table 1.
Patient characteristics of those with TRL (n = 4) and without TRL (n = 4)
| Patient | Age/sex | Histology | Tumor size (cm) | FIGO stagea | TNM stageb | Leukocyte count (/μL) | ANC (/μL) | ALC (/μL) | NLR (/μL) | Treatment | Recurrence | PFS (m) | OS (m) | Last f/u status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TRLpos 1 | 37/F | Squamous cell ca., non-keratinizing type | 7.0 | IIB (IIIB) | T2bN1 | 15,770 | 11,380 | 2650 | 4.29 | CCRT | None | 57.8 | 57.8 | Alive |
| TRLpos 2 | 35/F | Squamous cell ca., keratinizing type | 6.8 | IVA (IVA) | T4N1 | 9900 | 8470 | 530 | 15.98 | CCRT | Lung metastasis | 7.8 | 58.4 | Alive |
| TRLpos 3 | 66/F | Squamous cell ca., non-keratinizing type | 6.6 | IVA (IVA) | T4N1 | 11,850 | 9450 | 1660 | 5.69 | RT | Pelvic LN metastasis | 3.5 | 8.3 | Dead |
| TRLpos 4 | 28/F | Squamous cell ca., non-keratinizing type | 7.3 | IIA (IIIB) | T2a2N1 | 12,960 | 8250 | 2200 | 3.75 | CCRT | Lung metastasis | 7.5 | 16.5 | Dead |
| TRLneg 1 | 76/F | Squamous cell ca., non-keratinizing type | 1.9 | IIA1 (IIA1) | T2a1N0 | 6090 | 4200 | 1430 | 2.94 | CCRT | None | 57.8 | 57.8 | Alive |
| TRLneg 2 | 56/F | Squamous cell ca., non-keratinizing type | 5.0 | IB2 (IIIB) | T1b2N1 | 8010 | 3710 | 3340 | 1.11 | CCRT | None | 55.7 | 55.7 | Alive |
| TRLneg 3 | 75/F | Squamous cell ca., non-keratinizing type | 5.6 | IIB (IIIB) | T2bN1 | 8370 | 5300 | 2400 | 2.21 | CCRT | None | 60.8 | 60.8 | Alive |
| TRLneg 4 | 54/F | Squamous cell ca., non-keratinizing type | 3.1 | IIB (IIB) | T2bN0 | 7320 | 2970 | 3890 | 0.76 | CCRT | None | 69.4 | 69.4 | Alive |
TRL, tumor-related leukocytosis; ANC, absolute neutrophil count; ALC, absolute lymphocyte count; NLR, neutrophil-to-lymphocyte ratio; PFS, progression-free survival; OS, overall survival; CCRT, concurrent chemoradiotherapy; RT, radiotherapy; LN, lymph node
a2019 FIGO staging is provided in parenthesis
bAJCC 8th edition